162 related articles for article (PubMed ID: 7628887)
1. Chemical cardioversion of atrial fibrillation with intravenous dofetilide.
Sedgwick ML; Lip G; Rae AP; Cobbe SM
Int J Cardiol; 1995 Apr; 49(2):159-66. PubMed ID: 7628887
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
Singh S; Zoble RG; Yellen L; Brodsky MA; Feld GK; Berk M; Billing CB
Circulation; 2000 Nov; 102(19):2385-90. PubMed ID: 11067793
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
Bianconi L; Castro A; Dinelli M; Alboni P; Pappalardo A; Richiardi E; Santini M
Eur Heart J; 2000 Aug; 21(15):1265-73. PubMed ID: 10924317
[TBL] [Abstract][Full Text] [Related]
5. Dofetilide for atrial fibrillation.
Med Lett Drugs Ther; 2000 May; 42(1078):41-2. PubMed ID: 10847114
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter.
Lindeboom JE; Kingma JH; Crijns HJ; Dunselman PH
Am J Cardiol; 2000 Apr; 85(8):1031-3. PubMed ID: 10760352
[No Abstract] [Full Text] [Related]
7. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
McClellan KJ; Markham A
Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
[TBL] [Abstract][Full Text] [Related]
8. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
[TBL] [Abstract][Full Text] [Related]
9. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
Falk RH; Pollak A; Singh SN; Friedrich T
J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
[TBL] [Abstract][Full Text] [Related]
10. Positive atrial inotropic effect of dofetilide after cardioversion of atrial fibrillation or flutter.
DeCara JM; Pollak A; Dubrey S; Falk RH
Am J Cardiol; 2000 Sep; 86(6):685-8, A8. PubMed ID: 10980226
[TBL] [Abstract][Full Text] [Related]
11. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
Singh SN
Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
[TBL] [Abstract][Full Text] [Related]
12. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
[TBL] [Abstract][Full Text] [Related]
13. Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide.
Brumberg G; Gera N; Pray C; Adelstein E; Barrington W; Bazaz R; Mendenhall GS; Nemec J; Voigt A; Wang NC; Schwartzman D; Saba S; Jain SK
Am J Cardiol; 2013 Aug; 112(4):505-8. PubMed ID: 23706388
[TBL] [Abstract][Full Text] [Related]
14. Phase IV trial evaluating the effectiveness and safety of dofetilide.
Guanzon AV; Crouch MA
Ann Pharmacother; 2004; 38(7-8):1142-7. PubMed ID: 15161945
[TBL] [Abstract][Full Text] [Related]
15. Dofetilide-induced long QT and torsades de pointes.
Aktas MK; Shah AH; Akiyama T
Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
Frost L; Mortensen PE; Tingleff J; Platou ES; Christiansen EH; Christiansen N
Int J Cardiol; 1997 Jan; 58(2):135-40. PubMed ID: 9049678
[TBL] [Abstract][Full Text] [Related]
17. Dofetilide: a new class III antiarrhythmic agent.
Roukoz H; Saliba W
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
[TBL] [Abstract][Full Text] [Related]
18. Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.
Nagra BS; Ledley GS; Kantharia BK
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):191-5. PubMed ID: 16211208
[TBL] [Abstract][Full Text] [Related]
19. Considerations for dofetilide use in the elderly.
Crist LW; Dixon DL
Consult Pharm; 2014 Apr; 29(4):270-4. PubMed ID: 24704896
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.
Krahn AD; Klein GJ; Yee R
Pacing Clin Electrophysiol; 2001 Aug; 24(8 Pt 1):1258-60. PubMed ID: 11523612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
